MX2011012839A - Antagonistas policiclicos de receptores de acido lisofosfatidico. - Google Patents
Antagonistas policiclicos de receptores de acido lisofosfatidico.Info
- Publication number
- MX2011012839A MX2011012839A MX2011012839A MX2011012839A MX2011012839A MX 2011012839 A MX2011012839 A MX 2011012839A MX 2011012839 A MX2011012839 A MX 2011012839A MX 2011012839 A MX2011012839 A MX 2011012839A MX 2011012839 A MX2011012839 A MX 2011012839A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- lysophosphatidic acid
- acid receptors
- polycyclic
- compounds
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title 1
- 125000003367 polycyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente se describen compuestos que son antagonistas de receptores lifofosfatídicos. También se describen composiciones farmacéuticas y medicamentos que incluyen los compuestos descritos en la presente, así como métodos para utilizar tales antagonistas, solos o en combinación con otros compuestos, para tratar afecciones o enfermedades mediadas por LPA o dependientes de LPA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18378509P | 2009-06-03 | 2009-06-03 | |
| PCT/US2010/037309 WO2010141761A2 (en) | 2009-06-03 | 2010-06-03 | Polycyclic antagonists of lysophosphatidic acid receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012839A true MX2011012839A (es) | 2012-04-02 |
Family
ID=42471045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012839A MX2011012839A (es) | 2009-06-03 | 2010-06-03 | Antagonistas policiclicos de receptores de acido lisofosfatidico. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8058300B2 (es) |
| EP (1) | EP2438048B1 (es) |
| JP (1) | JP5599457B2 (es) |
| KR (2) | KR101774722B1 (es) |
| CN (2) | CN105061346A (es) |
| AU (2) | AU2010256501B2 (es) |
| BR (1) | BRPI1014582A2 (es) |
| CA (1) | CA2764445C (es) |
| CL (1) | CL2011003072A1 (es) |
| CO (1) | CO6480918A2 (es) |
| DK (1) | DK2438048T3 (es) |
| EA (1) | EA020139B1 (es) |
| ES (1) | ES2445714T3 (es) |
| GB (1) | GB2470833B (es) |
| HK (1) | HK1163085A1 (es) |
| HR (1) | HRP20140036T1 (es) |
| IL (2) | IL216220A (es) |
| MX (1) | MX2011012839A (es) |
| MY (1) | MY163055A (es) |
| NZ (1) | NZ596826A (es) |
| PE (1) | PE20120936A1 (es) |
| PL (1) | PL2438048T3 (es) |
| PT (1) | PT2438048E (es) |
| SG (1) | SG176112A1 (es) |
| SI (1) | SI2438048T1 (es) |
| SM (1) | SMT201400031B (es) |
| TW (1) | TWI405757B (es) |
| WO (2) | WO2010141761A2 (es) |
| ZA (1) | ZA201108421B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010068775A2 (en) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| WO2011017350A2 (en) | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| CN102548965B (zh) * | 2009-09-25 | 2014-04-09 | 安斯泰来制药株式会社 | 取代酰胺化合物 |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| US20120267025A1 (en) * | 2009-12-11 | 2012-10-25 | Guido Luigi Daghini | Tyre for a wheel of a heavy load vehicle |
| BR112013013950A2 (pt) * | 2010-12-07 | 2016-09-27 | Amira Pharmaceuticals Inc | antagonista de lpa1 policíclico e usos dos mesmos |
| CN103596947A (zh) | 2011-04-05 | 2014-02-19 | 艾米拉医药股份有限公司 | 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物 |
| JP2014525932A (ja) * | 2011-08-15 | 2014-10-02 | インターミューン， インコーポレイテッド | リゾホスファチド酸レセプターアンタゴニスト |
| WO2013070879A1 (en) * | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| BR112014012288A2 (pt) | 2011-11-22 | 2017-05-23 | Intermune Inc | métodos para diagnosticar e tratar fibrose pulmonar idiopática |
| WO2013189864A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-alkyltriazole compounds as lpar antagonists |
| AU2013279510A1 (en) * | 2012-06-20 | 2014-10-16 | F. Hoffmann-La Roche Ag | Substituted pyrazole compounds as LPAR antagonists |
| EP2925728A4 (en) * | 2012-11-27 | 2016-11-02 | Glaxosmithkline Llc | COMBINATION |
| CN107698555B (zh) | 2012-12-28 | 2020-05-05 | 宇部兴产株式会社 | 卤素取代杂环化合物 |
| US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| WO2014145873A2 (en) | 2013-03-15 | 2014-09-18 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| JP7467361B2 (ja) * | 2018-06-18 | 2024-04-15 | エピゲン バイオサイエンシズ，インコーポレイテッド | 疾患の治療に有用な複素環化合物 |
| WO2015066456A1 (en) | 2013-10-31 | 2015-05-07 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa-1 receptor |
| KR102433588B1 (ko) | 2014-06-27 | 2022-08-19 | 우베 가부시키가이샤 | 할로겐 치환 헤테로환 화합물의 염 |
| WO2016197009A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| MX2019012153A (es) * | 2017-04-10 | 2019-11-21 | Bayer Ag | N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso. |
| TWI770157B (zh) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| CA3106692A1 (en) * | 2017-07-19 | 2019-01-24 | Aazeintx Inc. | Method to abate acute airway hypersensitivity and asthma attacks |
| MX2020004930A (es) | 2017-11-14 | 2020-08-27 | Merck Sharp & Dohme | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). |
| EP3709986B1 (en) | 2017-11-14 | 2023-11-01 | Merck Sharp & Dohme LLC | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| WO2019126099A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| KR20210061383A (ko) | 2018-09-18 | 2021-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로펜틸 산 |
| EP3986553A1 (en) | 2019-06-18 | 2022-04-27 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as lpa antagonists |
| JP7422788B2 (ja) | 2019-06-18 | 2024-01-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのイソキサゾールカルボン酸 |
| CN114599648A (zh) | 2019-06-18 | 2022-06-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的三唑羧酸 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| KR102393079B1 (ko) | 2020-02-28 | 2022-04-29 | 한국화학연구원 | 가축 호흡기 질환의 예방 또는 치료용 조성물 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN114456157A (zh) * | 2020-11-10 | 2022-05-10 | 武汉人福创新药物研发中心有限公司 | 氮取代氨基碳酸酯噻吩类化合物及其用途 |
| TWI853704B (zh) | 2021-05-11 | 2024-08-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| AU2022405082A1 (en) | 2021-12-08 | 2024-07-11 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TW202432132A (zh) | 2022-12-23 | 2024-08-16 | 美商必治妥美雅史谷比公司 | 用於治療間質性肺病之lpa1拮抗劑 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| JP2001506271A (ja) | 1996-12-23 | 2001-05-15 | デュポン ファーマシューティカルズ カンパニー | Ｘａ因子阻害剤としての酸素またはイオウを含む複素環式芳香族化合物 |
| JP3237608B2 (ja) | 1997-04-21 | 2001-12-10 | 住友製薬株式会社 | イソキサゾール誘導体 |
| CA2368630A1 (en) | 1999-04-02 | 2000-10-12 | Ruth R. Wexler | Aryl sulfonyls as factor xa inhibitors |
| DE60137405D1 (de) | 2000-02-18 | 2009-03-05 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| ATE447970T1 (de) * | 2001-02-08 | 2009-11-15 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| WO2002092104A1 (en) * | 2001-04-25 | 2002-11-21 | Biosynergen, Inc. | A pharmaceutical composition comprising lysophosphatidic acid |
| JPWO2003007991A1 (ja) * | 2001-07-17 | 2004-11-04 | 小野薬品工業株式会社 | Ｌｐａ受容体調節剤からなる膵液分泌制御剤 |
| MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| WO2003055481A1 (fr) * | 2001-12-25 | 2003-07-10 | Ajinomoto Co., Inc. | Inhibiteurs de fibrose des organes |
| US20050261298A1 (en) * | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| US20050101518A1 (en) * | 2002-01-18 | 2005-05-12 | David Solow-Cordero | Methods of treating conditions associated with an EDG-2 receptor |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AU2003233119A1 (en) * | 2002-05-08 | 2003-11-11 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
| WO2003097047A1 (en) | 2002-05-13 | 2003-11-27 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| EP1533294A4 (en) * | 2002-05-28 | 2007-07-04 | Ono Pharmaceutical Co | BETA-ALANINE DERIVATIVE AND USE THEREOF |
| WO2004002530A1 (ja) * | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 慢性疾患治療剤 |
| WO2004031118A1 (ja) | 2002-10-03 | 2004-04-15 | Ono Pharmaceutical Co., Ltd. | Ｌｐａ受容体拮抗剤 |
| US20040171037A1 (en) * | 2002-11-19 | 2004-09-02 | Jing Li | Amplified genes involved in cancer |
| US20040167132A1 (en) * | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
| US20050065194A1 (en) * | 2003-01-16 | 2005-03-24 | Geetha Shankar | Methods of treating conditions associated with an Edg-2 receptor |
| US20040192739A1 (en) * | 2003-01-16 | 2004-09-30 | David Solow-Cordero | Methods of treating conditions associated with an Edg-2 receptor |
| US7135469B2 (en) * | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
| CA2521189A1 (en) | 2003-04-11 | 2004-10-28 | Gabor Tigyi | Lysophosphatidic acid analogs and inhibition of neointima formation |
| WO2004099164A1 (en) * | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
| JP4692281B2 (ja) * | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| WO2005032494A2 (en) | 2003-10-09 | 2005-04-14 | University Of Tennessee Research Foundation | Lpa receptor agonists and antagonists and methods of use |
| TW200521108A (en) | 2003-12-19 | 2005-07-01 | Ono Pharmaceutical Co | Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use |
| DE10360369A1 (de) | 2003-12-22 | 2005-07-14 | Bayer Cropscience Ag | Amide |
| US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| JP2006096712A (ja) | 2004-09-30 | 2006-04-13 | Senju Pharmaceut Co Ltd | Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤 |
| GB0511684D0 (en) * | 2005-06-08 | 2005-07-13 | Novartis Ag | Organic compounds |
| JP2008545767A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用 |
| US20090291988A1 (en) * | 2005-06-14 | 2009-11-26 | Renata Oballa | Reversible Inhibitors of Monoamine Oxidase A and B |
| WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| JP2009506046A (ja) | 2005-08-23 | 2009-02-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制剤化合物および組成物 |
| EP2013176A2 (en) * | 2006-02-27 | 2009-01-14 | Sterix Limited | Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| JP2009545531A (ja) | 2006-07-24 | 2009-12-24 | ユニバーシティ オブ バージニア パテント ファンデーション | ホスホン酸ビニルリゾホスファチジン酸受容体拮抗薬 |
| WO2008024979A2 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| US20080051372A1 (en) * | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| CA2672616A1 (en) * | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| US20100143381A1 (en) | 2007-03-12 | 2010-06-10 | Andrew Tager | Lysophosphatidic acid receptor targeting for lung disease |
| US9163091B2 (en) | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| KR101649482B1 (ko) | 2008-05-05 | 2016-08-19 | 사노피 | 아실아미노-치환된 융합된 사이클로펜탄카복실산 유도체 및 이들의 약제로서의 용도 |
| WO2010068775A2 (en) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| WO2011017350A2 (en) | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011159632A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
-
2010
- 2010-06-02 GB GB1009231A patent/GB2470833B/en not_active Expired - Fee Related
- 2010-06-03 JP JP2012514144A patent/JP5599457B2/ja not_active Expired - Fee Related
- 2010-06-03 NZ NZ596826A patent/NZ596826A/en not_active IP Right Cessation
- 2010-06-03 SG SG2011084589A patent/SG176112A1/en unknown
- 2010-06-03 TW TW099117993A patent/TWI405757B/zh not_active IP Right Cessation
- 2010-06-03 EA EA201101709A patent/EA020139B1/ru not_active IP Right Cessation
- 2010-06-03 SI SI201030496T patent/SI2438048T1/sl unknown
- 2010-06-03 KR KR1020167014623A patent/KR101774722B1/ko active IP Right Grant
- 2010-06-03 CN CN201510490659.4A patent/CN105061346A/zh active Pending
- 2010-06-03 WO PCT/US2010/037309 patent/WO2010141761A2/en active Application Filing
- 2010-06-03 ES ES10784122.3T patent/ES2445714T3/es active Active
- 2010-06-03 PE PE2011002041A patent/PE20120936A1/es active IP Right Grant
- 2010-06-03 PT PT107841223T patent/PT2438048E/pt unknown
- 2010-06-03 CN CN201080034419.9A patent/CN102459204B/zh not_active Expired - Fee Related
- 2010-06-03 PL PL10784122T patent/PL2438048T3/pl unknown
- 2010-06-03 US US12/793,440 patent/US8058300B2/en active Active
- 2010-06-03 AU AU2010256501A patent/AU2010256501B2/en not_active Ceased
- 2010-06-03 MY MYPI2011005870A patent/MY163055A/en unknown
- 2010-06-03 EP EP10784122.3A patent/EP2438048B1/en active Active
- 2010-06-03 CA CA2764445A patent/CA2764445C/en not_active Expired - Fee Related
- 2010-06-03 WO PCT/US2010/037316 patent/WO2010141768A2/en active Application Filing
- 2010-06-03 MX MX2011012839A patent/MX2011012839A/es active IP Right Grant
- 2010-06-03 BR BRPI1014582A patent/BRPI1014582A2/pt not_active Application Discontinuation
- 2010-06-03 DK DK10784122.3T patent/DK2438048T3/en active
- 2010-06-03 KR KR1020127000028A patent/KR101628706B1/ko not_active IP Right Cessation
-
2011
- 2011-09-27 US US13/246,746 patent/US8273780B2/en active Active
- 2011-11-08 IL IL216220A patent/IL216220A/en active IP Right Grant
- 2011-11-16 ZA ZA2011/08421A patent/ZA201108421B/en unknown
- 2011-12-02 CL CL2011003072A patent/CL2011003072A1/es unknown
- 2011-12-21 CO CO11176424A patent/CO6480918A2/es active IP Right Grant
-
2012
- 2012-04-17 HK HK12103740.3A patent/HK1163085A1/xx not_active IP Right Cessation
-
2014
- 2014-01-13 HR HRP20140036AT patent/HRP20140036T1/hr unknown
- 2014-03-14 SM SM201400031T patent/SMT201400031B/xx unknown
-
2015
- 2015-08-23 IL IL240749A patent/IL240749B/en not_active IP Right Cessation
-
2016
- 2016-04-27 AU AU2016202676A patent/AU2016202676B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| IN2012DN02177A (es) | ||
| IN2012DN00754A (es) | ||
| WO2010077882A3 (en) | Antagonists of lysophosphatidic acid receptors | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| WO2010068775A3 (en) | Alkyne antagonists of lysophosphatidic acid receptors | |
| PH12015501737B1 (en) | Androgen receptor modulators and uses thereof | |
| MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
| PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| WO2011156518A3 (en) | Estrogen receptor modulators and uses thereof | |
| MX2015016171A (es) | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. | |
| WO2014066799A3 (en) | Modulators of resistant androgen receptor | |
| UA96037C2 (ru) | Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |